Biologics Research Review, Issue 31 - Dermatology focus

In this issue:

Anti-PD-1: reduced risk of AEs after ipilimumab for metastatic melanoma
New primary cutaneous melanoma after immune checkpoint inhibitors
Panitumumab for unresectable cutaneous SCC
Dupilumab for paediatric severe atopic dermatitis
Dupilumab for treatmentrefractory atopic dermatitis
Patient- and physicianreported outcomes in moderate-to-severe plaque psoriasis
COVID-19 skin diseases and biologics
COVID-19 and TNF inhibitors and/or methotrexate
Etanercept biosimilar in patients with psoriatic arthritis

Please login below to download this issue (PDF)

Subscribe